Asformin

Quick links to important sections

Asformin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asformin

Quick Facts

Property Description
Active Ingredient Metformin Hydrochloride
Form Oral Tablet
Pharmacological Class Biguanides (Antidiabetic Agent)
Origin Synthetic Compound
Common Use Managing high blood sugar (hyperglycemia)

What Type of Medicine is Asformin?

Asformin is a foundational, synthetic pharmaceutical preparation containing the single-ingredient active component, Metformin Hydrochloride. It belongs to the pharmacological class known as biguanides and is administered as an oral tablet. This medication is classified as an antidiabetic agent and is typically a prescription-only medicine, emphasizing the necessity of medical oversight for its use.

Its classification as a biguanide is characterized by an established profile in managing blood sugar. Metformin is considered a core therapy for chronic disease management.


Composition and General Purpose

The core of Asformin is its Metformin Hydrochloride content, which is combined with solid excipients to create the final oral dosage form. Due to Metformin's long history and widespread use, this formulation is often employed in situations where high blood sugar is a persistent issue, supporting the body's ability to process glucose.

The overall purpose of Asformin is to help the body maintain healthy, balanced blood sugar levels, thereby counteracting hyperglycemia. This medication addresses glucose imbalance by enhancing the body’s sensitivity to insulin and suppressing the liver's production of glucose. This action plays a critical role in supporting the body's natural processes of sugar regulation.

Regulatory References

  1. National Library of Medicine Metformin Review

What side effects are possible with Asformin?

Possible Side Effects and Safety Information

The safety profile of Asformin (Metformin Hydrochloride) is classified based on official regulatory documents, highlighting reactions by frequency and affected physiological system. The most common adverse reactions involve the Gastrointestinal system, and these effects are officially noted as Very Common (ge 1/10). This category includes diarrhea, nausea, vomiting, abdominal pain, and loss of appetite. These gastrointestinal issues are often transient and are more frequently observed at the beginning of treatment or during dose adjustments.


Less frequent effects are classified as Common (ge 1/100 to < 1/10), which primarily includes taste disturbance (e.g., metallic taste). A number of clinically significant events are classified as Very Rare (< 1/10,000). The most serious is Lactic Acidosis, a severe metabolic complication tied to Metformin accumulation, which is primarily a risk in patients with severe renal impairment.


Safety constraints concerning renal function are central to the drug's label, with an explicit contraindication for use in individuals with a severely decreased estimated Glomerular Filtration Rate (eGFR). Long-term use is associated with a very rare potential for decreased Vitamin B12 absorption, which can lead to hematological or neurological issues; therefore, periodic monitoring is required. Additionally, a note exists for Females of Reproductive Potential, indicating that the medication may stimulate ovulation, which could lead to unintended pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Asformin (Metformin Hydrochloride) overdose focuses primarily on the risk of a severe metabolic complication known as Lactic Acidosis (MALA). This condition is potentially life-threatening and is characterized by elevated blood lactate levels, decreased blood pH, hypotension, and can progress to coma.

Documented Overdose Manifestations

Initial overdose presentations often include nonspecific systemic symptoms and gastrointestinal distress. These manifestations, which may precede severe acidosis, include malaise, somnolence (drowsiness), muscle pain (myalgias), nausea, vomiting, and abdominal pain. Hypoglycemia (low blood sugar) has also been reported in some cases.


Emergency Actions and High-Risk Notes

Official guidance mandates that individuals must seek immediate medical attention and withdraw the medication if these signs of potential overdose or acidosis occur. Hemodialysis is documented as the definitive procedural intervention for removing the accumulated drug and correcting severe acidosis, as no specific antidote is known.

Overdose risk and severity are noted to be increased in patients with pre-existing renal impairment, hepatic impairment, or advanced age, as these conditions impair the body's ability to clear the drug, leading to accumulation.

Therapeutic Uses of Asformin

What Asformin Treats: Main Uses and Benefits

Asformin (Metformin Hydrochloride) is commonly used to manage chronic metabolic conditions where patients experience symptoms related to systemic imbalance, particularly concerning glucose regulation. It is frequently utilized as a starting point for medical management of Type 2 Diabetes Mellitus, and is also relevant in cases of Prediabetes (Impaired Glucose Tolerance) and for the metabolic management of Polycystic Ovary Syndrome (PCOS).

The medication provides support that assists with easing the symptom burden related to chronic high blood sugar and may help maintain a sense of metabolic stability.

“This medication is considered relevant for patients needing assistance in managing complex metabolic symptoms that interfere with daily functioning.”

In these contexts, its use helps address symptom clusters related to chronic glucose overload, and is relevant for helping to manage symptoms of androgen excess, such as acne and hirsutism, often seen in women with PCOS. It is commonly used when supportive symptom management is appropriate to support the mitigation of long-term physiological strain.


Quick Fact: Relief for Chronic Glucose Imbalance

Property Description
Primary Indication Management of Type 2 Diabetes Mellitus
Symptom Goal Addressing persistently high blood sugar levels
Secondary Benefit May assist with supporting menstrual regularity in PCOS

Eligibility and Restrictions for Use

Who can and cannot use Asformin?

Regulatory labeling establishes strict eligibility for Asformin (metformin hydrochloride) based on patient status, age, and organ function, primarily to manage the risk of lactic acidosis.


Contraindicated and Restricted Use

Classification Regulatory Condition
Contraindicated Severe renal impairment (eGFR below 30 mL/min/1.73 m^2), acute or chronic metabolic acidosis (including diabetic ketoacidosis), and known hypersensitivity [Source 1.1].
Not Recommended Starting the medicine in patients with an eGFR between 30 and 45 mL/min/1.73 m^2, or in patients with hepatic impairment [Source 1.1, 1.2].

Population-Specific Eligibility

Asformin is approved for use in adults and pediatric patients 10 years of age and older with Type 2 Diabetes Mellitus [Source 2.2].

  • Children under 10 years of age are a use-not-established group, as safety and effectiveness have not been determined [Source 2.1].
  • Older adults require frequent monitoring of renal function. The medicine is contraindicated if renal function declines below the severe impairment threshold [Source 1.5].
  • Pregnant and breastfeeding patients should consult official health guidelines; metformin is present in breast milk, and premenopausal women should be advised of the potential for unintended pregnancy [Source 1.7, 3.5].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Asformin (Metformin Hydrochloride) has documented interactions with substances that affect its renal elimination or alter blood sugar levels, as defined by regulatory bodies.

Official Regulatory Interaction Classifications

Classification Interacting Substance/Condition
Contraindicated Excessive alcohol intake (acute or chronic)
Timing Restriction Procedures using iodinated contrast agents
Timing Restriction Elective surgery requiring general anesthesia

Documented Exposure and Effect Changes

Interactions often center on the competition for renal tubular transport systems (e.g., OCT2, MATE). Co-administration with certain medicines, such as Cimetidine, Ranolazine, and Dolutegravir, is officially documented to increase Metformin systemic exposure by inhibiting its clearance.

Co-use with Carbonic Anhydrase Inhibitors (e.g., Topiramate) is noted to elevate the risk of Lactic Acidosis. When combined with other blood-glucose-lowering agents, such as Insulin or Sulfonylureas, an additive pharmacodynamic effect results, increasing the risk of hypoglycemia. Medicines with intrinsic hyperglycaemic activity, like Glucocorticoids, may reduce Asformin's efficacy. Long-term use may also lower serum Vitamin B12 levels. These interactions require careful consideration.

Mechanism of Action

Core Mechanism: Suppression of Hepatic Glucose Output

Asformin (Metformin) primarily acts by accumulating in hepatocytes (liver cells) via the OCT1 transporter where it indirectly activates the enzyme AMP-activated protein kinase (AMPK). This activation results from a mild inhibition of the Mitochondrial Complex I, which modifies the cellular energy ratio. The resulting AMPK cascade modulates the activity and expression of key enzymes necessary for making glucose (gluconeogenesis), thus reducing the rate of endogenous glucose production.


Enhancement of Peripheral Insulin Sensitivity

The activated AMPK signal extends to peripheral tissues, including muscle and fat cells, affecting their metabolic state. This mechanism facilitates the translocation of GLUT4 transporters to the cell surface, promoting tissue glucose uptake and utilization from the circulation. This action is a mechanism contributing to enhanced cellular sensitivity to insulin without directly promoting the hormone's secretion.


️ Modulation of Gut-Mediated Effects

Additionally, the drug affects the gastrointestinal tract, leading to a minor reduction in the absorption of glucose from the intestine. This local action is associated with enhanced secretion of certain gut hormones, such as GLP-1, which serves as a contributing factor in the overall modulation of systemic glucose homeostasis.

Dosage and Administration Information

How to Use Asformin

Asformin (Metformin Hydrochloride) is consistently administered via the oral route as either an immediate-release (IR) or extended-release (ER) tablet formulation.


Official Dosing and Administration Protocol

The usage protocol is based on a structured titration schedule and precise timing relative to meals.

Usage Entity Dosing and Administration Details
Route & Form Oral tablet only (IR or ER forms).
Starting Dose (Adult IR) Typically 500 mg twice daily or 850 mg once daily.
Maintenance Dose Range 1500 mg to 2550 mg per day for IR tablets.
Dosing Frequency IR tablets are taken in divided doses (two or three times daily); ER tablets are taken once daily.

The treatment is typically initiated with a low dose and gradually increased (titrated) to the maintenance range, often in increments of 500 mg weekly or 850 mg every two weeks, to maximize patient tolerability. This titration defines the long-term frequency and amount of medication used.


Contextual Use and Adjustments

All tablet forms must be taken with meals, which is a key administration constraint to support tolerance. Specifically, Extended-Release tablets must be swallowed whole and are explicitly restricted from being crushed, cut, or chewed. The protocol involves specific dose modifications for certain populations: in cases of renal impairment, the dose is constrained and must be reduced or discontinued based on the patient's estimated Glomerular Filtration Rate (eGFR). If a regular dose is missed, the standard protocol is to skip the missed dose and resume the normal schedule, without taking a double dose to compensate. The medication is generally intended for long-term chronic management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asformin


Evidence for use in Major Depressive Disorder (MDD)

Research regarding Asformin included short-term Randomized Controlled Trials (RCTs). These are studies where participants with MDD were assigned randomly to receive either Asformin or a comparison treatment, often for a period of four to eight weeks. The populations included in the main studies were primarily adults diagnosed with moderate to severe depression. These trials research examined outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level, using tools like standardized symptom severity scales.

Studies report how symptom measurements progressed in the observed populations over these defined time intervals. The findings describe patterns observed in the studies regarding the proportion of participants who reached a pre-defined symptom measurement endpoint by the end of the short period. Research highlights changes measured during the short study period, and data suggest that long-term status is not represented.


Evidence for use in Generalized Anxiety Disorder (GAD)

Asformin was evaluated in research concerning GAD through a mix of short-term RCTs and associated meta-analyses. This research was evaluated in outpatients aged 18 and older diagnosed with GAD, a condition where symptoms may vary in intensity. Researchers used standardized anxiety rating scales to measure outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Since the findings were mixed across some comparative studies, and the follow-up was brief, the current evidence remains limited for understanding long-term status.


Long-term Studies and Follow-up

There is limited information for long-term outcomes that cover more than a few months, as research has generally focused on periods of acute or short-term symptom change. The evidence provides context for group patterns observed, but does not determine whether an individual outcome will align similarly over several years. The study duration means that outcomes related to sustained status over extended periods are not fully established.


What is still uncertain about Asformin

The evidence highlights areas where more research is needed. Long-term effects are not fully established, and follow-up durations were limited in many main trials. Data for special populations, such as children and adolescents, remain insufficient, and the effects in older adults have not been widely or rigorously explored. Research is needed to better characterize outcomes linked to chronic, persistent forms of the studied conditions.

Frequently Asked Questions (FAQ)

Common questions about Asformin (FAQ)


Q: Is Asformin the same type of medicine as [similar sounding/competitor drug]?

Official classifications categorize Asformin, which contains Metformin, in the Biguanides pharmacological class. It is noted in regulatory documents that this compound is the only one in the Biguanides class currently available for use. This classification is based on the drug's established mechanism of action for managing blood sugar.


Q: Do the side effects of Asformin usually go away after the first week?

Gastrointestinal side effects, such as nausea or diarrhea, are the most common adverse reactions and are frequently reported when treatment is started or the dose is adjusted. Official information indicates that taking the medicine with meals may help reduce these effects. They are often described as transient, meaning they typically resolve over time. Official information suggests this resolution usually occurs during the initial weeks of use.


Q: What happens if I forget to take a dose of Asformin?

The official protocol described in the prescribing information states that the patient should skip the dose that was missed and continue with the next scheduled dose at the normal time. It is explicitly advised against taking a double dose to compensate for the skipped one.


Q: Is it true that Asformin can cause weight changes, and is it weight gain or loss?

Studies and official information indicate that Asformin treatment is generally not associated with weight gain, unlike some other medicines used for blood sugar management. In fact, clinical findings sometimes observe a modest weight loss in individuals taking the medication.


Q: How quickly does Asformin leave the body after the last dose?

Pharmacokinetic data—the study of how the body processes the drug—is defined in official product documents. These documents state that the plasma elimination half-life of the active ingredient, Metformin, is approximately 6.2 hours. This figure describes the time it typically takes for half of the substance to be eliminated from the bloodstream.


Q: Can Asformin cause sun sensitivity or skin reactions?

Official safety information documents serious allergic reactions as a very rare possibility when taking this medicine. These reactions can sometimes involve the skin and may manifest as a rash, hives, or swelling of the face, lips, or tongue. Official safety documents describe that serious allergic reactions require immediate medical review.


Q: Why is Asformin sometimes used in combination with other medicines for the same condition?

Regulatory documents indicate that Asformin is approved for use alone or in combination with other medicines used to lower blood sugar, such as insulin. The purpose of this combination is to leverage their additive pharmacodynamic effects to achieve better overall blood sugar control than either medicine could achieve alone.


Q: Are there any known risks if Asformin is used by women who are pregnant or breastfeeding?

Official labeling advises that the drug passes into breast milk in small amounts. Additionally, women of reproductive age should be advised that the medicine may stimulate ovulation, which could potentially lead to an unintended pregnancy. Blood sugar control during pregnancy is important, and a healthcare provider should be consulted regarding management.


Q: Are there any serious or rare side effects of Asformin that I should be aware of?

The most serious, very rare complication noted in regulatory information is Lactic Acidosis, a severe metabolic condition. Other risks that require monitoring include the potential for decreased Vitamin B12 absorption with long-term use. There is also an increased risk of hypoglycemia (very low blood sugar) when Asformin is used with other specific blood sugar-lowering medicines.


Q: Can I take Asformin at the same time as my daily vitamins or herbal supplements?

Official labeling advises all patients to inform their healthcare provider of all concomitant products they are using. This includes prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. This step is advised so the provider can assess for potential interactions and determine if any adjustments may be necessary.


Q: Will Asformin interact with blood pressure or cholesterol medicines?

Regulatory documents highlight potential interactions with certain medicines. These include drugs that affect renal tubular transport systems (how the kidneys eliminate the drug) or medicines that have intrinsic hyperglycaemic activity (meaning they can raise blood sugar, such as Glucocorticoids). Official labeling provides a comprehensive list of known interacting substances.


Q: Is there a maximum time frame I can safely take Asformin for?

Regulatory guidelines indicate that Asformin is a medicine generally intended for long-term chronic management of blood sugar levels. There is no specific maximum duration of use cited in the official label, provided the patient’s eligibility and renal function are consistently monitored by a healthcare provider.


Q: Has Asformin been studied in populations with existing kidney or liver problems?

Regulatory information notes that severe renal (kidney) or hepatic (liver) impairment significantly increases the risk of serious complications and is considered a contraindication for use. Recent revisions to official labeling were based on studies examining use in mild to moderate renal impairment to better inform prescribing practices.


Q: Is Asformin considered habit-forming or addictive?

Official regulatory product information, including controlled substance schedules, does not contain documentation indicating that Asformin is a controlled substance. Therefore, it is not described as having the potential for abuse or dependence.


Q: Do clinical trials of Asformin show any rare long-term effects that develop years later?

Official documents describe that long-term use may result in a very rare decrease in Vitamin B12 absorption, which requires monitoring. For many other potential effects, the general information regarding long-term outcomes remains limited due to the duration of most main clinical trials, which focused on shorter periods of observation.


Q: What is the expected average improvement or outcome when taking Asformin?

Clinical research has examined various outcomes in patients taking Asformin. These include measurements related to systemic or functional imbalance and measures that reflect daily functioning or activity level. These outcomes are tracked and measured using standardized symptom severity scales defined by researchers.


Q: Are there any religious or dietary restrictions I need to consider while using Asformin?

Official administration guidelines state that all tablet forms of Asformin must be taken with meals. Patients are advised to discuss any dietary, fasting, or cultural requirements that affect their meal schedule with their healthcare provider, as consistency in administration is necessary.


Q: How does my weight influence the use or effects of Asformin?

Regulatory-cited research and clinical guidance note that Asformin is an effective initial choice for patients who are classified as overweight or obese. The medicine works by enhancing the body's sensitivity to insulin in tissues like muscle and fat, and it is typically not associated with weight gain.


Q: Does Asformin require dose adjustments for people of different ages?

Official prescribing guidelines require frequent monitoring of renal function in older adults, as their kidney function can affect the drug’s clearance and may necessitate dose adjustment. The medicine is also approved for use in pediatric patients 10 years of age and older, following specific pediatric dosing protocols.


How should Asformin be stored and disposed of?

How to Store and Dispose of Asformin (Metformin Hydrochloride)

Official regulatory guidelines dictate specific conditions for storing and discarding Asformin tablets to maintain stability and ensure safety.


Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (mathbf20^circC to mathbf25^circC / mathbf68^circF to mathbf77^circF)
Protection Keep in a tight, light-resistant container; protect from light and moisture.
Child Safety Keep out of the sight and reach of children using a child-resistant closure.

Disposal

Unused or expired Asformin must be disposed of according to local regulations. The product should not be discarded in household waste, sewage, or wastewater to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asformin found in:

A-Z Index: